

IN THE SPECIFICATION**AMENDMENTS TO THE SPECIFICATION**

1. Please amend paragraph 18 as follows:

[0018] or a bombesin analog according to the formula:

-Gln-Trp-Ala-Ala-βAla-His-Phe-Nle-NH₂; (SEQ ID NO: 8)
 -Gln-Trp-Ala-Val-Gly-His-Leu-Ψ(CH₂-NH)-Leu-NH₂; (SEQ ID NO: 9)
 -Gln-Trp-Ala-Val-Gly-His-Leu-Ψ(CH₂-NH)-Phe-NH₂; (SEQ ID NO: 10)
 -Gln-Trp-Ala-Val-βAla-His-Leu-Leu-NH₂; (SEQ ID NO: 11)
 -Gln-Trp-Ala-Val-βAla-His-Leu-Nle-NH₂; (SEQ ID NO: 12)
 -Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH₂; (SEQ ID NO: 13)
 -Gln-Trp-Ala-Val-βAla-His-Ala-Nle-NH₂; (SEQ ID NO: 14)
 -Gln-Trp-Ala-Val-βAla-Ala-Phe-Nle-NH₂; (SEQ ID NO: 15)
 -Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH₂; (SEQ ID NO: 1)
 -Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂; (SEQ ID NO: 2)
 -Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH₂; (SEQ ID NO: 3)
 -DAla-Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH₂;
 -DPhe-Gln-Trp-Ala-Ala-βAla-His-Phe-Nle-NH₂;
 -DPhe-Gln-Trp-Ala-Val-βAla-Ala-Phe-Nle-NH₂;
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH₂;
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH₂;
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Ala-Nle-NH₂;
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Leu-Leu-NH₂;
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Leu-Nle-NH₂;
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Ψ(CH₂-NH)-Leu-NH₂;
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Ψ(CH₂-NH)-Phe-NH₂;
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂;
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH₂;
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH₂; or

or a pharmaceutically acceptable salt thereof.

2. Please delete the original Sequence Listing and insert the Substitute Sequence Listing included herewith.